Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2022-04-06 00:00:00 ET · period of report 2022-04-04 · accession 0000950142-22-001324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-06 | 2022-04-04 | LAB | Casdin Eli | Dir, 10% | A - Grant | $0.00 | +15.9K | 15.9K | New | $0 |
| D | 2022-04-06 | 2022-04-04 | LAB | Casdin Eli | Dir, 10% | A - Grant | $0.00 | +23.4K | 23.4K | New | $0 |
| DI | 2022-04-06 | 2022-04-04 | LAB | Casdin Eli | Dir, 10% | A - Grant | — | +127.8K | 127.8K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-04 | A | A | 15,852 | $0.00 | 15,852 | D | — | — | (F1) Represents Restricted Stock Units that vest in four equal annual increments beginning April 4, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-04-04 | A | A | 23,401 | $0.00 | 23,401 | D | $3.99 · — to 2032-04-04 | 23,401 Common Stock | (F5) The Option becomes exercisable in four equal annual increments beginning on April 4, 2023. |
| 3 | Derivative | Series B-1 Convertible Preferred Stock | 2022-04-04 | A | A | 127,780 | — | 127,780 | I See footnote | — · — to — | 37,582,346 Common Stock | (F3) On April 4, 2022, the Issuer issued the Series B-1 Preferred Stock (i) in exchange for aggregate cash consideration of $112.5 million, pursuant to the Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, among the Issuer, Casdin Partners Master Fund, L.P. ("Casdin Master Fund") and Casdin Private Growth Equity Fund II, L.P. ("Casdin Private Growth Fund") and (ii) upon the conversion of $12.5 million aggregate principal amount of term loans, including accrued and unpaid interest, pursuant to the Series B-1 Loan Agreement, dated as of January 23, 2022, among the Issuer, Casdin Master Fund and Casdin Private Growth Fund. (F4) These shares are held by Casdin Master Fund and Casdin Private Growth Fund. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Master Fund and Casdin Private Growth Fund. Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Master Fund and Casdin Private Growth Equity Fund II GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Fund. Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP and Casdin Private Growth GP. Each of Casdin Capital, Casdin Partners GP, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. (F2) Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock. |